Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03223727
Other study ID # m15RTO
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 30, 2015
Est. completion date February 3, 2023

Study information

Verified date April 2023
Source The Netherlands Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This registry aims to evaluate the efficacy of Rad-223 treatment in a non-study population of CRPC patients treated earlier with Docetaxel and patients not treated earlier with Docetaxel and efficacy of the first subsequent therapy. The indication for treatment with Radium-223 will be at the physician's decision. All patients treated with Radium-223 can be included in this registry. The registry only dictates the collection of base line characteristics, expansion of regular blood tests and patient reported pain scores.


Description:

Serum and blood markers of bone metabolism will be evaluated at Base Line, 1st, 2nd, 3rd and 6th (or last) Radium- 223 treatment. Every blood draw prior to Radium-223 treatment At baseline, tests include (but not restricted to): Testosterone, vitamin D-25-OH (Calciferol), C-reactive protein, Rank Ligand, IL6, BSAF, P1NP and CTX. Patients need to be fasting when blood is collected. (2x8,5 ml gel tube; Limited to 100 patients in selected centres). Before 2nd, 3rd, 4th and 6th (or last) Radium-223 treatment, tests include (but not restricted to): C-reactive protein, Rank, Ligand, IL6, BSAF, P1NP and CTX. Patients need to be fasting when blood is collected. (2x8,5 ml gel tube; Limited to 100 patients in selected centers). Moreover, levels of osteoclast precursors (CD34+) will be evaluated (10 ml heparinized blood) prior to the first Radium-223 treatment, 3rd and last treatment (Limited to 100 patients in selected centres). All above-mentioned blood collections will be from the same venipuncture as standard clinical labs. Experimental assessments will be evaluated for their value as biomarkers of treatment outcome.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date February 3, 2023
Est. primary completion date February 3, 2022
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - At the physicians discretion - Age 18 year and older. - Written informed consent Exclusion Criteria: - Previous treatment with Radium-223. - Participation in another Radium-223 study.

Study Design


Intervention

Diagnostic Test:
Blood tests
Blood tests for several bone markers (see summary)

Locations

Country Name City State
Netherlands The Netherlands Cancer Intitute Amsterdam
Netherlands Franciscus Gasthuis & Vlietland Rotterdam

Sponsors (2)

Lead Sponsor Collaborator
The Netherlands Cancer Institute Bayer

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of treatment on pain outcomes, as mentioned by the patient Evaluate Radium-223 treatment efficacy by patient, by several questionnaires (FACT-P, BPI-S and use of painmedication). through study completion, an average of 1 year. (6 months treatment, 6 months follow-up after end of treatment)
Primary Efficacy of treatment by patient records But also by patient records (records of bonescans, CT scans, blood measurements, out-patient clinic visits).
All of these assessments will be combined to come to a final reported value (Progressive disease, stable disease, partial remission or complete remission)
through study completion, an average of 1 year. (6 months treatment, 6 months follow-up after end of treatment)
Secondary Symptomatic Skeletal Event To evaluate the efficacy of Radium-223 treatment in a nonstudy population by effects on Symptomatic Skeletal Event (SSE). Through patient records and questionnairs (FACT-P, BPI-S and use of painmedication). through study completion, an average of 1 year. (6 months treatment, 6 months follow-up after end of treatment)
Secondary Clinical Parameters assessed by the WHO PS. Evaluate Radium-223 treatment efficacy in a non-study population of CRPC patients by clinical parameters, through patient records (WHO PS) through study completion, an average of 1 year. (6 months treatment, 6 months follow-up after end of treatment)
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Evaluate Radium-223 treatment tolerability in a non-study population of CRPC patients, through patient records (using the CTCAE v4.03 for adverse events). through study completion, an average of 1 year. (6 months treatment, 6 months follow-up after end of treatment)
Secondary Subsequent therapy after Radium-223: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Evaluate of the treatment after Radium-223 the treatment tolerability in a non-study population of CRPC patients, through patient records (using the CTCAE v4.03 for adverse events). through study completion, an average of 1 year. (6 months treatment, 6 months follow-up after end of treatment)
Secondary Biomarkers Identification of predictive clinical and explorative biomarkers of Radium-223 efficacy through study completion, an average of 1 year. (6 months treatment, 6 months follow-up after end of treatment)
See also
  Status Clinical Trial Phase
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Active, not recruiting NCT01996046 - FDG PET/CT in Breast Cancer Bone Mets
Completed NCT01358539 - Palliation: the Effect of Education on Pain Phase 3
Terminated NCT00981578 - ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain N/A
Terminated NCT00757757 - A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases Phase 1/Phase 2
Completed NCT00762346 - Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Phase 4
Completed NCT00420433 - Bone Response in Metastatic Breast Cancer Involving Bones N/A
Completed NCT02826382 - Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 Early Phase 1
Terminated NCT05301062 - A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Recruiting NCT06367491 - National Database of Bone Metastases
Completed NCT00830180 - Open Label Extension In Cancer Patients Phase 2
Active, not recruiting NCT03305224 - The Combination Therapy With Ra-223 and Enzalutamide Phase 2
Withdrawn NCT04109937 - External Beam Radiation Therapy Post Surgery in Patients With Lower Extremity Bone Metastases Randomized Efficacy Trial N/A
Active, not recruiting NCT02880943 - Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL) Phase 1/Phase 2
Completed NCT01696760 - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology N/A
Completed NCT00958477 - A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer Phase 1
Completed NCT03979118 - Exercise Prescription in Patients With Bone Metastases
Completed NCT03353090 - Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients N/A
Recruiting NCT05167669 - Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU Early Phase 1
Recruiting NCT04568291 - CTC in Lung Caner Patients With Bone Metastases N/A